Zeneca Posts Strong Growth In Germany
UK drug company Zeneca's subsidiary in Germany posted sales growth of 6% to 743 million Deutschemarks ($502.6 million) for 1995 with operating profits stable at 63 million marks. Zeneca GmbH increased turnover from 605 million marks to 622 million marks, mainly due to a 13% hike for drug specialties to 163 million marks.
Overall German drug sales went up 8% to 488 million marks. The company says its German achievement is due to the success of its newer, patent-protected drugs whose share of sales went up last year from 59% to 65%. Older products posted losses.
The current year is being assessed very positively, with a good start in the first two months of 1996. Zeneca expects to report above-average growth this year on the German drug market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze